• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Bicara, Zenas and MBX rekin­dle IPO mar­ket with rare Fri­day triple­head­er

8 months ago
Financing
Startups

Cor­rect­ed: Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-L1

8 months ago
Pharma
FDA+

Seres' mi­cro­bio­me ther­a­py re­duces in­fec­tions in stem cell trans­plant pa­tients, but next steps are un­clear

8 months ago
R&D

FDA re­vis­its new struc­ture for drug re­view doc­u­ments, aim­ing to bet­ter ex­plain its de­ci­sions

8 months ago
FDA+

Avadel's nar­colep­sy drug Lum­ryz miss­es PDU­FA date, still un­der re­view at FDA

8 months ago
Pharma
FDA+

FDA should em­brace new ways of eval­u­at­ing rare dis­ease drugs, re­port ar­gues

8 months ago
Pharma
FDA+

Aus­tralian RNA man­u­fac­tur­er launch­es; Forge Bi­o­log­ics’ CEO steps down

8 months ago
Manufacturing

De­bio­pharm, ITM ink up to €300M li­cens­ing deal for can­cer treat­ment

8 months ago
Deals

GSK’s mR­NA flu shot is head­ing to Phase 3; Sum­mit’s $235M of­fer­ing

8 months ago
News Briefing

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

8 months ago
R&D

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

8 months ago
People
Manufacturing

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

8 months ago
Financing
Startups

Lil­ly bud­gets $1.8B to boost Kisun­la, GLP-1 man­u­fac­tur­ing in Ire­land

8 months ago
Manufacturing

Gilead says twice-year­ly HIV pre­ven­tion shot suc­ceeds in sec­ond piv­otal tri­al

8 months ago
R&D
Pharma

Noom of­fers com­pound­ed GLP-1 drugs, promis­es pa­tients can quit and keep weight off

8 months ago
Pharma
Health Tech

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

8 months ago
Financing
Startups

F2G inks $100M Se­ries H for an­oth­er shot at treat­ing fun­gal in­fec­tions

8 months ago
Financing
Startups

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

8 months ago
R&D

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

8 months ago
R&D

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

8 months ago
Deals
R&D

J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

8 months ago
Pharma
FDA+

CVS says it won't cor­rect con­gres­sion­al tes­ti­mo­ny

8 months ago
Law

No­vo Nordisk's long­stand­ing GLP-1 re­duced BMI by 7% in chil­dren in Phase 3 tri­al

8 months ago
R&D

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

8 months ago
Pharma
FDA+
First page Previous page 979899100101102103 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times